Aspen Surgical Products Receives Additional Investment from Audax Private Equity

Aspen Surgical Products (“Aspen”), a portfolio company of Audax Private Equity (“Audax”), announced today that Audax has closed on a single-asset continuation fund to support additional investment in Aspen and reaffirming its commitment to supporting the company’s long-term growth strategy.

Since Audax’s original investment in 2019, Aspen has tripled the scale of the company by acquiring five complementary businesses, further developing and diversifying its sales channel, and accelerating innovative product line extensions. This new investment will allow Audax to continue to support the Aspen executive leadership team as it pursues imminent organic growth and larger-scale acquisition opportunities in order to

“A little over two years ago we embarked on a journey to dramatically enhance our value with our hospital customers and channel partners,” said Jason Krieser, CEO of Aspen. “I couldn’t be happier with our success to date. This transaction represents an excellent return for our original investors, while empowering our Aspen Surgical organization to continue to progress in our mission of improving safety and efficiency for clinicians at an even faster rate.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.